4446 related articles for article (PubMed ID: 6334654)
1. Possible association between HLA-DR5 and superficial spreading melanoma (SSM).
Mueller-Eckhardt G; Schendel DJ; Hundeiker M; Riedel T; O'Neill GJ; Riethmüller G; Mueller-Eckhardt C
Int J Cancer; 1984 Dec; 34(6):751-5. PubMed ID: 6334654
[TBL] [Abstract][Full Text] [Related]
2. Class III alleles and high-risk MHC haplotypes in type I diabetes mellitus, Graves' disease and Hashimoto's thyroiditis.
Skanes VM; Barnard J; Farid N; Marshall WH; Murphy L; Rideout D; Taylor R; Xidos G; Larsen B
Mol Biol Med; 1986 Apr; 3(2):143-57. PubMed ID: 3461234
[TBL] [Abstract][Full Text] [Related]
3. HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis.
Pollack MS; Livingston PO
Tissue Antigens; 1985 Oct; 26(4):262-5. PubMed ID: 3878014
[TBL] [Abstract][Full Text] [Related]
4. Major histocompatibility complex class II and complement polymorphisms in postpartum thyroiditis.
Parkes AB; Darke C; Othman S; Thomas M; Young N; Richards CJ; Hall R; Lazarus JH
Eur J Endocrinol; 1996 Apr; 134(4):449-53. PubMed ID: 8640296
[TBL] [Abstract][Full Text] [Related]
5. HLA antigens in familial and sporadic cutaneous melanoma.
Rovini D; Pellegris G; Cascinelli N; Cantoni L; Vaglini M; Placucci M; Santinami M; Belli F; Illeni MT
Tumori; 1988 Dec; 74(6):657-64. PubMed ID: 3232210
[TBL] [Abstract][Full Text] [Related]
6. Major histocompatibility complex markers and red cell antibodies to the Rh (D) antigen. Absence of association.
Kruskall MS; Yunis EJ; Watson A; Awdeh Z; Alper CA
Transfusion; 1990 Jan; 30(1):15-9. PubMed ID: 2104997
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies and immunogenetics in 30 patients with systemic sclerosis and their families.
Pereira S; Black C; Welsh K; Ansell B; Jayson M; Maddison P; Rowell N
J Rheumatol; 1987 Aug; 14(4):760-5. PubMed ID: 3499513
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for lentigo maligna melanoma compared with superficial spreading melanoma: a case-control study in Australia.
Kvaskoff M; Siskind V; Green AC
Arch Dermatol; 2012 Feb; 148(2):164-70. PubMed ID: 22004881
[TBL] [Abstract][Full Text] [Related]
9. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic dynamics of tumor progression in human malignant melanoma.
Bröcker EB; Suter L; Brüggen J; Ruiter DJ; Macher E; Sorg C
Int J Cancer; 1985 Jul; 36(1):29-35. PubMed ID: 3860479
[TBL] [Abstract][Full Text] [Related]
11. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
[TBL] [Abstract][Full Text] [Related]
12. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma.
Luongo V; Pirozzi G; Caracò C; Errico S; de Angelis F; Celentano E; Paino F; Chiofalo MG; Luongo M; Mozzillo N; Lombardi ML
Tissue Antigens; 2004 Jul; 64(1):84-7. PubMed ID: 15191529
[TBL] [Abstract][Full Text] [Related]
13. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.
Campillo JA; Martínez-Escribano JA; Muro M; Moya-Quiles R; Marín LA; Montes-Ares O; Guerra N; Sánchez-Pedreño P; Frías JF; Lozano JA; García-Alonso AM; Alvarez-López MR
Immunogenetics; 2006 Jan; 57(12):926-33. PubMed ID: 16365741
[TBL] [Abstract][Full Text] [Related]
14. Antigenic phenotype of radial growth phase melanomas with or without a vertical growth phase portion.
Brogelli L; Carli P; Reali UM; Pimpinelli N; Moretti S
Tumori; 1988 Apr; 74(2):157-62. PubMed ID: 3285554
[TBL] [Abstract][Full Text] [Related]
15. Etiological differences between subtypes of cutaneous malignant melanoma: Western Canada Melanoma Study.
Elwood JM; Gallagher RP; Worth AJ; Wood WS; Pearson JC
J Natl Cancer Inst; 1987 Jan; 78(1):37-44. PubMed ID: 3467128
[TBL] [Abstract][Full Text] [Related]
16. Molecular heterogeneity of second and fourth components of complement and their genes in systemic sclerosis and association of HLA alleles A1, B8 and DR3 with limited and DR5 with diffuse systemic sclerosis.
Venneker GT; van den Hoogen FH; van Meegen M; de Kok-Nazaruk M; Hulsmans RF; Boerbooms AM; de Waal LP; Bos JD; Asghar SS
Exp Clin Immunogenet; 1998; 15(2):90-9. PubMed ID: 9691203
[TBL] [Abstract][Full Text] [Related]
17. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
[TBL] [Abstract][Full Text] [Related]
18. Increased frequency of HLA-DR5 in scleroderma.
Gladman DD; Keystone EC; Baron M; Lee P; Cane D; Mervert H
Arthritis Rheum; 1981 Jun; 24(6):854-6. PubMed ID: 6972768
[No Abstract] [Full Text] [Related]
19. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack MS; Heagney SD; Livingston PO; Fogh J
J Natl Cancer Inst; 1981 Jun; 66(6):1003-12. PubMed ID: 7017212
[TBL] [Abstract][Full Text] [Related]
20. HLA-D antigens in a Czech population and their association with HLA-DR antigens.
Hinzová E; Ivasková E; Cukrová V; Rychlíková M
Folia Biol (Praha); 1980; 26(4):267-74. PubMed ID: 6773825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
